Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Randomised, Parallel Group, Multicentre, Non-inferiority Study to Compare ZOLADEX 10.8 mg With ZOLADEX 3.6 mg in Chinese Pre-menopausal Patients With Estrogen Receptor-Positive and HER2 Negative Early Breast Cancer

Next Previous
Search
Trial Profile

An Open Label, Randomised, Parallel Group, Multicentre, Non-inferiority Study to Compare ZOLADEX 10.8 mg With ZOLADEX 3.6 mg in Chinese Pre-menopausal Patients With Estrogen Receptor-Positive and HER2 Negative Early Breast Cancer

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Goserelin (Primary)
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LARES
  • Sponsors AstraZeneca

    • Most Recent Events

    • 06 May 2021 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: CTP of LARES has been out of the expire date, the investigators are trying RWS pathway for the indication expend.
    • 19 Dec 2019 Planned End Date changed from 31 Dec 2020 to 4 Nov 2021.
    • 19 Dec 2019 Planned primary completion date changed from 31 Dec 2020 to 4 Nov 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top